体征总体评估与体表面积的乘积在特应性皮炎中的初步验证
本研究通过回顾性病历分析,在138例特应性皮炎患者共325次门诊就诊中评估SGA×BSA的测量性能,发现其与EASI、瘙痒、患者总体评估等呈强相关,严重度分级界值为1、21、87,提示其可作为临床实践中评估体征严重度的简易工具。
要点
- SGA×BSA与EASI强相关(r=0.91,n=19),支持其作为体征严重度指标。
- 严重度分级界值为1、21、87(κ=0.4902),可用于临床分级。
- 该工具简便可行,适合临床实践快速评估特应性皮炎体征。
核心结论
- SGA×BSA是临床实践中评估特应性皮炎体征有效且可行的工具。
研究设计与样本
- 回顾性病历分析,纳入2015至2018年俄勒冈健康与科学大学门诊皮肤科138例特应性皮炎患者共325次就诊。
主要发现
- 严重度分级界值为1、21、87(κ=0.4902)。
关键数值与推荐
- 可接受性、反应性及地板/天花板效应均判定为充分。
- 严重度分级界值为1、21、87(κ=0.4902)。
临床怎么用
- 临床可用SGA×BSA快速评估特应性皮炎体征严重度。
- 依据界值1、21、87进行严重度分级。
局限性
- 患者队列仅来自太平洋西北地区三级保健门诊,缺乏种族多样性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current valid instruments that measure the signs of atopic dermatitis in clinical trials may not be suitable for clinical practice because of their complexity. The product of a clinician-derived 5-point signs global assessment and body surface area (SGA × BSA) may represent a simple approach to quickly assess the severity of signs in patients with atopic dermatitis in clinical practice. OBJECTIVES: Evaluate the basic measurement properties of the SGA × BSA. METHODS: Retrospective chart review of patients with atopic dermatitis treated in an outpatient dermatology clinic at Oregon Health & Science University from 2015 to 2018 who had a recorded BSA and SGA. RESULTS: We identified 138 patients completing 325 clinic visits. SGA × BSA demonstrated strong and statistically significant (P < .001) correlations with the Eczema Area and Severity Index (r = 0.91, n = 19), average daily pruritus (r = 0.71, n = 177), patient global assessment (r = 0.74, n = 170), and a derived global scale composed of the average of 4 signs rated between 0 and 3 (r = 0.77, n = 282). Acceptability, responsiveness, and floor or ceiling effects of the measure were deemed adequate. Severity banding was maximized at 1, 21, and 87 (κ = 0.4902). LIMITATIONS: The patient cohort was gathered exclusively from a tertiary care clinic setting in the Pacific Northwest and lacked ethnic diversity. CONCLUSIONS: The results from this study suggest that SGA × BSA is a valid and feasible instrument for atopic dermatitis signs in clinical practice.
引用
- Topham C, Haynes D, Brazil M, et al. Initial validation of the product of the signs global assessment and body surface area in atopic dermatitis. J Am Acad Dermatol. 2020. PMID: 32454101. doi:10.1016/j.jaad.2020.05.095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。